Related Experiment Video

Updated: Aug 15, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Agents targeting ras signaling pathway

J E Dancey1

  • 1Cancer Therapy Evaluation Program, National Cancer Institute, 6130 Executive Blvd, EPN 7131, Rockville, MD 20852, USA. danceyj@ctep.nci.nih.gov

Current Pharmaceutical Design
|October 9, 2002
PubMed

Insights

Mutated Ras oncogenes drive cancer by affecting cell growth and survival. New drugs targeting Ras signaling pathways, including Raf and MEK, are in development to treat various human malignancies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Ras genes are crucial in intracellular signaling networks regulating cell differentiation, proliferation, and survival.
  • Mutated Ras oncogenes lead to constitutively active proteins, driving malignancy in laboratory models.
  • Ras mutations are prevalent in human cancers, occurring in approximately 30% of cases.

Purpose of the Study:

  • To review recent advancements in the development of therapeutic agents targeting the Ras signaling pathway.
  • To highlight agents that disrupt signaling through Ras and its downstream effectors, Raf and MEK.

Main Methods:

  • Agents are classified structurally as small molecules and anti-sense oligonucleotides.
  • Agents are functionally categorized by their mechanism of action: inhibiting Ras protein expression, Ras processing, or downstream effectors.
  • Specific examples include ISIS 2503 (oligodeoxynucleotide), farnesyl transferase inhibitors (R115777, SCH 66336, BMS 214662), ISIS 5132 (Raf inhibitor), and CI-1040 (MEK inhibitor).

Main Results:

  • A variety of agents targeting Ras and downstream proteins (Raf, MEK) are under active development.
  • These agents represent diverse structural and functional approaches to disrupt oncogenic signaling.
  • The development pipeline includes inhibitors of Ras expression, processing, and downstream effector functions.

Conclusions:

  • Targeting the Ras signaling pathway is a key strategy in cancer therapy due to the high frequency of Ras mutations in human malignancies.
  • Ongoing development of novel agents offers promising therapeutic options for cancers driven by Ras pathway activation.
  • Further research and clinical evaluation are essential to realize the full potential of these anti-cancer agents.

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...